Trial | NCT00788424  Report issue

Title

Topical Application of AS101 for the Treatment of Psoriasis
Study of Topical Application of AS101 for the Treatment of Psoriasis

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Intervention/Treatment

    as-101 ...

  • Study Participants

    0
This protocol relates to a phase II randomized double blind, placebo controlled study of the AS101 topical application for the treatment of mild to moderate Psoriasis.
Study Started
Nov 30
2008
Primary Completion
Feb 28
2010
Study Completion
Feb 28
2010
Last Update
Jul 23
2015
Estimate

Drug AS101 Cream

4% AS101 Cream or Placebo cream, twice a day for 12 weeks

AS101 Cream Experimental

Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.

Placebo Experimental

Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.

Criteria 

Inclusion Criteria:

Patient have a diagnosed mild to moderate stable plaque type psoriasis (less than 10% of body skin surface).
Patient must be 18-70 years of age.
General health must be adequate to allow for compliance with the requirements of this protocol.
Patient or his/her legal guardian must sign an informed consent form prior to study participation.
Patient must be able and willing to comply with all protocol requirements.

Exclusion Criteria:

Patients who are mentally disabled or are otherwise unable to provide fully informed consent.
Pregnant or breast-feeding females.
Patients with evidence of an infection in the targeted zones.
Patients with known sensitivity to any of the drug components.
Patients treated by systemic anti psoriatic medications within one month prior to the initial treatment with the AS101, or topical anti psoriatic preparations within two weeks prior to the initial treatment with the AS101.
Patient with psoriatic arthritis.
Patients taking immunosuppressive drugs.
Immunocompromised patients
No Results Posted